Garg PK, O’Neal WT, Chen LY, Loehr LR, Sotoodehnia N, Soliman EZ, Alonso A. American Heart Association’s Life Simple 7 and Risk of Atrial Fibrillation in a Population Without Known Cardiovascular Disease: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2018;7.

Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang N-Y, Yaffe K, Martin SS. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022;145.

Lutsey PL, Norby FL, Alonso A, Cushman M, Chen LY, Michos ED, Folsom AR. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the atherosclerosis risk in communities Study. J Thromb Haemost. 2018;16:670–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel NJ, Deshmukh A, Pant S, Singh V, Patel N, Arora S, Shah N, Chothani A, Savani GT, Mehta K, Parikh V, Rathod A, Badheka AO, Lafferty J, Kowalski M, Mehta JL, Mitrani RD, Viles-Gonzalez JF, Paydak H. Contemporary Trends of Hospitalization for Atrial Fibrillation in the United States, 2000 through 2010. Circulation. 2014;129:2371–9.

Article  PubMed  Google Scholar 

Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen A-M, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411–23.

Article  PubMed  Google Scholar 

De Corte W, Dhondt A, Vanholder R, De Waele J, Decruyenaere J, Sergoyne V, Vanhalst J, Claus S, Hoste EAJ. Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study. Crit Care. 2016;20:256.

Article  PubMed  PubMed Central  Google Scholar 

Shawwa K, Kompotiatis P, Bobart SA, Mara KC, Wiley BM, Jentzer JC, Kashani KB. New-onset atrial fibrillation in patients with acute kidney injury on continuous renal replacement therapy. J Crit Care. 2021;62:157–63.

Article  CAS  PubMed  Google Scholar 

Shaver CM, Chen W, Janz DR, May AK, Darbar D, Bernard GR, Bastarache JA, Ware LB. Atrial fibrillation is an independent predictor of Mortality in critically ill patients. Crit Care Med. 2015;43:2104–11.

Article  PubMed  PubMed Central  Google Scholar 

Moss TJ, Calland JF, Enfield KB, Gomez-Manjarres DC, Ruminski C, DiMarco JP, Lake DE, Moorman JR. New-Onset Atrial Fibrillation in the critically ill. Crit Care Med. 2017;45:790–7.

Article  PubMed  PubMed Central  Google Scholar 

Hellman T, Uusalo P, Järvisalo MJ. New-onset atrial fibrillation in critically ill acute kidney injury patients on renal replacement therapy. EP Europace. 2021;24:211–7.

Article  Google Scholar 

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the heart rhythm society in collaboration with the Society of thoracic surgeons. Circulation. 2019;140.

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64.

Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S, Thurston C, Vedantham S, Verhamme P, Witt DM, Izcovich IDF, Nieuwlaat A, Ross R, Wiercioch SHJS, Zhang W, Zhang Y. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–738.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Troy A, Anderson TS. National trends in Use of and spending on oral anticoagulants among US Medicare beneficiaries from 2011 to 2019. JAMA Health Forum. 2021;2.

Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and Variation in oral anticoagulant choice in patients with Atrial Fibrillation, 2010–2017. Pharmacotherapy. 2018;38:907–20.

Article  PubMed  PubMed Central  Google Scholar 

Wetmore JB, Roetker NS, Yan H, Reyes JL, Herzog CA. Direct-acting oral anticoagulants Versus Warfarin in Medicare patients with chronic kidney Disease and Atrial Fibrillation. Stroke. 2020;51:2364–73.

Article  CAS  PubMed  Google Scholar 

Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;11.

Al Rowily A, Jalal Z, Price MJ, Abutaleb MH, Almodiaemgh H, Al Ammari M, Paudyal V. Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78:623–45.

Article  PubMed  Google Scholar 

Sanghai S, Wong C, Wang Z, Clive P, Tran W, Waring M, Goldberg R, Hayward R, Saczynski JS, McManus DD. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with Atrial Fibrillation: the SAGE‐AF Study. J Am Heart Assoc. 2020;9.

Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA, Non-Vitamin K. Antagonist oral anticoagulant dosing in patients with Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69:2779–90.

Article  CAS  PubMed  Google Scholar 

Sato T, Aizawa Y, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Okabe M. The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with Atrial Fibrillation: from the database of a single-Center Registry. J Stroke Cerebrovasc Dis. 2018;27:3280–8.

Article  PubMed  Google Scholar 

Moudallel S, Steurbaut S, Cornu P, Dupont A. Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for Inappropriate Prescribing. Front Pharmacol. 2018;9.

Rohla M, Pecen L, Cemin R, Patti G, Siller-Matula JM, Schnabel RB, Huber K, Kirchhof P, De Caterina R, Reclassification. Thromboembolic, and major bleeding outcomes using different estimates of renal function in anticoagulated patients with Atrial Fibrillation: insights from the PREFER in AF and PREFER in AF PRO Long-Term registries. J Am Heart Assoc. 2022;11.

Chen A, Stecker E, Warden A. B. Direct oral anticoagulant use: a practical guide to Common Clinical challenges. J Am Heart Assoc. 2020;9.

Lindner SM, Fitzgerald BM. Direct oral anticoagulants. StatPearls. Treasure Island. (FL): StatPearls Publishing; 2023.

Google Scholar 

Singh T, Maw TT, Henry BL, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013;8(9):1533–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pacchiarini MC, Regolisti G, Greco P et al. Treatment of dabigatran intoxication in critically ill patients with acute kidney Injury: the role of sustained low-efficiency Dialysis. Int J Artif Organs 2023 Oct-Nov;46(10–11):574–80.

Artunc F, Muehlbacher T, Baumann D, et al. Removal of dabigatran is superior by sustained low efficient dialysis (SLED) compared to intermittent hemodialysis. Blood Purif. 2015;39(4):331–2.

Article  PubMed  Google Scholar 

Sheikh-Taha M. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury. Am J Health Syst Pharm. 2019;76(1):9–12.

Article  PubMed  Google Scholar 

Andrews L, Benken S, Tan X, Wenzler E. Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy. BMC Nephrol. 2021;22(1):45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dalmastri V, Angelini A, Minerva V, Ballarini M, Grammatico F, Todeschini P, Pizzini AM, Silingardi M, La Manna G. Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report. J Med Case Rep. 2023;17(1):283.

Article  PubMed Central  Google Scholar 

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.

Article  PubMed  Google Scholar 

Beavers CJ, Cios DA, Dang D, Haines ST, Page RL. Safety and efficacy of anticoagulation in patients with atrial fibrillation and chronic kidney disease. Heart Rhythm. 2019;16:472–7.

Google Scholar 

Fazio G, Dentamaro I, Gambacurta R, Alcamo P, Colonna P. Safety of edoxaban 30 mg in elderly patients with severe renal impairment. Clin Drug Investig. 2018;38(11):1023–30.

Article  CAS  PubMed  Google Scholar 

Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E, Investigators E-T. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation. 2016;134:24–36.

Article  CAS  PubMed  Google Scholar 

Hart RG, Eikelboom JW, Brimble KS, McMurtry S, Ingram AJ, Herzog CA. Stroke Prevention in Atrial Fibrillation patients with chronic kidney disease. Can J Cardiol. 2013;29.

Olesen JB, Lip GYH, Lane DA, Køber L, Hansen ML, Karasoy D, Gislason GH, Torp-Pedersen C. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med. 2012;125:826. e13-826. e23.

Article  Google Scholar 

Food and Drug Administration Center for Drugs Evaluation Research. Guidance for Industry: Pharmacokinetics in patients with impaired renal function — study design, Data Analysis, and impact on dosing and labeling. U.S. Department of Health and Human Services; 2010.

Roberts DM, Liu X, Roberts JA, Nair P, Cole L, Roberts MS, Lipman J, Bellomo R. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care. 2015;19:84.

Article  PubMed  Google Scholar 

Anonymous PRISMAFLEX, System, M60/M100/M150 Hemofilter Sets, on Baxter Healthcare Corporation. 2016. https://econnect.baxter.com/assets/downloads/products_expertise/renal_therapies/PRISMAFLEX_System_M60_M100_M150.pdf. Accessed 12 June.

Anonymous, PRISMAFLEX System HF1000/HF1400 Hemofilter Sets, on Baxter Healthcare Corporation. 2016. https://econnect.baxter.com/assets/downloads/products_expertise/renal_therapies/Prismaflex_HF_Spec_Sheet.pdf. Accessed 12 June.

Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor xa inhibitor, in humans. Drug Metab Dispos. 2012;40:2250–5.

Article  CAS  PubMed  Google Scholar 

Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and safety of the factor xa inhibitor Edoxaban and the effects of Quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:358–66.